Biophysics of Protein-Mediated Membrane Fusion

蛋白质介导的膜融合的生物物理学

基本信息

  • 批准号:
    8503961
  • 负责人:
  • 金额:
    $ 10.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1996
  • 资助国家:
    美国
  • 起止时间:
    1996-08-01 至 2012-09-27
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): HIV envelope (Env) protein deposits the nucleocapsid into a host cell by mediating fusion between the viral and cell membranes. Fusion is promoted through conformational changes in Env, which are triggered upon sequential interactions with CD4 and coreceptors. The intermediate steps of HIV fusion that can be targeted by drugs and antibodies are not fully understood, owing to the limited structural information on Env and to the lack of real-time techniques to monitor HIV-cell fusion. An additional complication is that the infectious entry pathways of this virus are not well defined. Whereas HIV is thought to infect cells by fusing directly with a plasma membrane, an accumulating body of evidence suggests that infection can also occur via pH- independent fusion with endosomal compartments. This project focuses on examining HIV entry pathways and on delineating the progression of fusion through intermediate stages. Virus-cell fusion will be directly monitored by the viral core-associated enzyme delivery assay. Individual steps of HIV-cell fusion will be dissected by time-of-addition experiments, using a panel of entry inhibitors targeting CD4 and coreceptor binding steps, as well as the membrane fusion step itself. The contribution from intracellular fusion will be examined by blocking virus endocytosis or by inhibiting both exoplasmic and endoplasmic fusion pathways. Time-resolved imaging of single virus-cell fusion will also be employed to elucidate pathways of HIV entry. Our imaging data suggest that fusion pores formed by individual HIV particles at the cell surface do not fully enlarge, whereas those formed with endosomal membranes dilate efficiently, permitting the release of viral content into the cytosol. These differences in the propensity of fusion pores to dilate have led to the hypothesis that HIV has adapted to form relatively small pores at designated sites, but relies on endocytic machinery to enlarge these pores and initiate infection. In order to test this hypothesis, the formation and enlargement of Env-induced fusion pores at the cell surface and in endosomes will be examined and the roles of viral and cellular factors in dilating these pores will be evaluated. The proposed approaches will help delineate the pathways of HIV fusion that culminate in the release of viral nucleocapsid and will elucidate key intermediate steps of this process. PUBLIC HEALTH RELEVANCE: Human immunodeficiency virus (HIV) initiates infection by depositing its genome into a host cell - a process that involves fusion of the membrane surrounding the viral core with a cell membrane. Membrane fusion is a complex multi-step reaction mediated by specialized HIV envelope protein (Env). To elucidate the mechanism of Env-induced membrane fusion, single HIV particles will be visualized by time-resolved fluorescence microscopy and their fusion with a host cell will be monitored from its initiation (a local merger of viral and cellular membranes) to completion (release of the viral genome into the cytosol). These studies will help define the entry mechanisms of HIV and will suggest new strategies to prevent infection.
描述(由申请人提供):HIV包膜(Env)蛋白通过介导病毒和细胞膜之间的融合将核衣壳沉积到宿主细胞中。融合是通过Env的构象变化来促进的,这是在与CD4和辅助受体的连续相互作用下触发的。由于有限的Env结构信息和缺乏实时监测HIV细胞融合的技术,目前还不完全了解HIV融合的中间步骤,这些步骤可以被药物和抗体靶向。另一个并发症是,这种病毒的感染进入途径没有很好地确定。虽然HIV被认为是通过直接与质膜融合来感染细胞,但越来越多的证据表明,感染也可以通过与内体腔室的pH无关的融合发生。这个项目的重点是检查艾滋病毒的进入途径,并通过中间阶段描绘融合的进展。病毒-细胞融合将通过病毒核相关酶递送试验直接监测。hiv细胞融合的各个步骤将通过添加时间实验进行剖析,使用一组靶向CD4和辅助受体结合步骤的进入抑制剂,以及膜融合步骤本身。细胞内融合的作用将通过阻断病毒内吞作用或抑制外质和内质融合途径来检验。单病毒-细胞融合的时间分辨成像也将用于阐明HIV的进入途径。我们的成像数据表明,单个HIV颗粒在细胞表面形成的融合孔不会完全扩大,而那些与内体膜形成的融合孔会有效地扩张,从而允许病毒内容物释放到细胞质中。融合孔扩张倾向的这些差异导致了一种假设,即HIV已经适应在指定位置形成相对较小的孔,但依赖于内吞机制来扩大这些孔并引发感染。为了验证这一假设,我们将研究环境诱导的细胞表面和核内体融合孔的形成和扩大,并评估病毒和细胞因子在扩大这些孔中的作用。所提出的方法将有助于描述以病毒核衣壳释放为高潮的HIV融合途径,并将阐明这一过程的关键中间步骤。公共卫生相关性:人类免疫缺陷病毒(HIV)通过将其基因组沉积到宿主细胞中引发感染,这一过程涉及围绕病毒核心的膜与细胞膜的融合。膜融合是由HIV特异性包膜蛋白介导的一个复杂的多步骤反应。为了阐明env诱导的膜融合机制,将通过时间分辨荧光显微镜观察单个HIV颗粒,并监测它们与宿主细胞的融合,从开始(病毒和细胞膜的局部合并)到完成(病毒基因组释放到细胞质中)。这些研究将有助于确定艾滋病毒的进入机制,并将提出预防感染的新策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gregory B Melikian其他文献

Gregory B Melikian的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gregory B Melikian', 18)}}的其他基金

Biophysics Core
生物物理学核心
  • 批准号:
    10508448
  • 财政年份:
    2022
  • 资助金额:
    $ 10.96万
  • 项目类别:
Biophysics Core
生物物理学核心
  • 批准号:
    10650878
  • 财政年份:
    2022
  • 资助金额:
    $ 10.96万
  • 项目类别:
Molecular Interactions of HIV-1 with the Nuclear Pore Complex
HIV-1 与核孔复合物的分子相互作用
  • 批准号:
    10241258
  • 财政年份:
    2019
  • 资助金额:
    $ 10.96万
  • 项目类别:
Molecular Interactions of HIV-1 with the Nuclear Pore Complex
HIV-1 与核孔复合物的分子相互作用
  • 批准号:
    10462620
  • 财政年份:
    2019
  • 资助金额:
    $ 10.96万
  • 项目类别:
Inhibition of viral entry by interferon-induced proteins
干扰素诱导蛋白抑制病毒进入
  • 批准号:
    10418696
  • 财政年份:
    2018
  • 资助金额:
    $ 10.96万
  • 项目类别:
Inhibition of viral entry by interferon-induced proteins
干扰素诱导蛋白抑制病毒进入
  • 批准号:
    10190798
  • 财政年份:
    2018
  • 资助金额:
    $ 10.96万
  • 项目类别:
Imaging of Single HIV-1 Uncoating and Transport to the nucleus
单个 HIV-1 脱壳和转运至细胞核的成像
  • 批准号:
    9354023
  • 财政年份:
    2017
  • 资助金额:
    $ 10.96万
  • 项目类别:
Kinetic Determinants of HIV Neutralization
HIV 中和的动力学决定因素
  • 批准号:
    7929311
  • 财政年份:
    2010
  • 资助金额:
    $ 10.96万
  • 项目类别:
Kinetic Determinants of HIV Neutralization
HIV 中和的动力学决定因素
  • 批准号:
    8142878
  • 财政年份:
    2010
  • 资助金额:
    $ 10.96万
  • 项目类别:
Functional Characterization of the Hepatitis C Virus E1-E2 Glycoproteins
丙型肝炎病毒 E1-E2 糖蛋白的功能表征
  • 批准号:
    7522862
  • 财政年份:
    2009
  • 资助金额:
    $ 10.96万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 10.96万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 10.96万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 10.96万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.96万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 10.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 10.96万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 10.96万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 10.96万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 10.96万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 10.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了